Compare Harmony Gold Mining Co. (HMY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Novo Nordisk A/S — how do they compare? Harmony Gold Mining Co. trades at $15.31 (market cap $9.07B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 24.3× Harmony Gold Mining Co.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| HMY | NVO | |
|---|---|---|
Market Cap | $9.07B | $220.53B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $71.70 |
52-Week Low | $12.61 | $35.29 |
Enterprise Value | $9.41B | $239.49B |
Dividend Yield | 2.84% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $14.37, down 1.91% on the day, amid a bearish technical signal and mixed sentiment. The company shows strong fundamentals with a P/E of 9.37, net income margin of 20.06%, and robust cash flow from operations of $15.65 billion in 2024. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while revenue grew to $61.38 billion in 2024. A dividend of $0.31 is scheduled for payment in May 2026, adding income appeal.
Outlook is cautious due to technical weakness and analyst skepticism (70% hold rating), but valuation metrics and profitability support potential upside if gold prices stabilize. Key risks include Fed rate sensitivity and operational execution amid the transition to a gold-copper hybrid model. The stock presents a value opportunity with manageable debt, though near-term volatility may persist.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
